APOE ε4–associated heterogeneity of neuroimaging biomarkers across the Alzheimer’s disease continuum

by Clinical Neuropsychologist Online | Friday, November 22, 2024 | Dementia

Abstract INTRODUCTION While the role of apolipoprotein E (APOE) ε4 in Alzheimer’s disease (AD) susceptibility has been studied extensively, much less is known about the differences in disease presentation in APOE ε4 carriers versus non-carriers. METHODS To help...

Biological validation of peak‐width of skeletonized mean diffusivity as a VCID biomarker: The MarkVCID Consortium

by Clinical Neuropsychologist Online | Thursday, November 21, 2024 | Dementia

Abstract BACKGROUND Peak-width of skeletonized mean diffusivity (PSMD), a neuroimaging marker of cerebral small vessel disease (SVD), has shown excellent instrumental properties. Here, we extend our work to perform a biological validation of PSMD. METHODS We included...

Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium

by Clinical Neuropsychologist Online | Wednesday, November 20, 2024 | Dementia

Abstract Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer’s disease (AD) patients. The AMYPAD consortium set out to integrate...

Visual read of [F‐18]florquinitau PET that includes and extends beyond the mesial temporal lobe is associated with increased plasma pTau217 and cognitive decline in a cohort that is enriched with risk for Alzheimer’s disease

by Clinical Neuropsychologist Online | Tuesday, November 19, 2024 | Dementia

Abstract INTRODUCTION Patterns of signal from tau positron emission tomography (tau-PET) confined to the medial temporal lobe (MTL) or extended into the neocortex may be relevant for Alzheimer’s disease (AD) research if they are linked to differential biomarker...

Conversion to Alzheimer’s disease dementia from normal cognition directly or with the intermediate mild cognitive impairment stage

by Clinical Neuropsychologist Online | Tuesday, November 19, 2024 | Dementia

Abstract INTRODUCTION Progression to Alzheimer’s disease (AD) dementia from normal cognition (NC) can follow different trajectories, with most progressing through a recognizable mild cognitive impairment stage (NC–MCI–AD), while some individuals transition...

Neighborhood physical activity facilities predict risk of incident mixed and vascular dementia: The Cardiovascular Health Cognition Study

by Clinical Neuropsychologist Online | Tuesday, November 19, 2024 | Dementia

Abstract INTRODUCTION Neighborhood environments may promote neurocognitive health in part by providing amenities that encourage physical activity. We examined associations between quantity of walkable facilities, including specifically physical activity facilities...